Company | Mondelez International, Inc. |
Ticker | MDLZ (NASDAQ) |
Reporting Period | Q2 2026 (quarter ending June 30, 2026) |
Expected Earnings Date | Late July / Early August 2026 |
Last Earnings Date | April 28, 2026 (Q1 2026) |
Prepared Date | July 27, 2026 |
Sector ETF (Benchmark) | XLP — Consumer Staples Select Sector SPDR |
Key Takeaway: The setup into Q2 2026 is modestly constructive but not a high bar — consensus organic growth of ~0.75% is achievable given Q1 momentum, but the single biggest swing factor is whether North America biscuit volumes show the sequential improvement management guided for, or whether the Middle East-driven consumer confidence deterioration deepens the category softness.
Heading into Q2 2026, the bar for MDLZ is deliberately low: consensus organic revenue growth sits at just ~0.75% (vs. 3.0% in Q1 2026), reflecting the market's skepticism about North America's recovery trajectory and the lingering drag from Middle East conflict-related cost headwinds. Management reaffirmed full-year guidance on the Q1 call rather than raising it, explicitly signaling that any EPS upside would be reinvested into the business — a posture that caps near-term earnings upside but builds credibility for the 2027 recovery thesis. Estimate revisions have been essentially flat since the Q1 print, with Q2 organic growth consensus barely moving from the post-earnings baseline (~0.96% to ~0.75%), suggesting the Street has already priced in a soft quarter and is not positioned for a meaningful beat. The stock has gained ~3.6% since the Q1 earnings date (vs. XLP +2.7%), trading in a narrow range of $57–$64, implying the market is neither pricing in a beat nor a miss — the multiple remains compressed relative to historical averages, reflecting ongoing concern about margin recovery timing. The key wildcard is emerging markets momentum: Q1 EM organic growth of 6.3% was well above the full-year guidance range, and if Q2 sustains that pace — particularly with India's GST tailwind still partially in effect and Brazil/China improving — MDLZ could deliver a revenue beat even if North America disappoints.
Key Takeaway: Consensus sets a low bar for Q2 2026 — organic growth of ~0.75% vs. 3.0% in Q1 and 5.6% in Q2 2025 is easily beatable if emerging markets sustain momentum. Volume/mix is the bigger swing factor: consensus expects -1.2% vs. the -0.5% (ex-downsizing) delivered in Q1, and any positive surprise here would be a meaningful signal that the volume recovery is ahead of schedule.
KPI | Q1 2026 Actual (Last Quarter) | Q2 2025 Actual (Prior Year) | Q2 2026 Consensus Estimate | YoY Change | FY 2026 Guidance | Consensus vs. Guidance |
Net Revenue ($B) | $10.08B | $8.98B | $9.23B | +2.7% YoY | ~$39.9–40.1B FY | In line |
Organic Revenue Growth (%) | 3.0% | 5.6% | 0.75% | -485 bps YoY | Low single-digit | Below midpoint |
Volume/Mix (%) | -0.5% | -1.5% | -1.2% | +30 bps YoY | Sequential improvement | N/A (no explicit guidance) |
Gross Profit - Operating ($B) | $3.09B | $3.03B | $3.02B | -0.3% YoY | Margin recovery in H2 | Slightly below prior year |
Adj. EPS (Diluted-Operating) ($) | $0.67 | $0.73 | $0.68 | -6.8% YoY | ~$3.04–3.05 FY | In line with FY run-rate |
Free Cash Flow ($B) | $0.16B | $0.003B | $1.16B | Large YoY improvement | ~$3.2B FY | Tracking to FY target |
Source: Visible Alpha Consensus and Actuals Data
Quarter | Reported | Consensus | Surprise (bps) | Result |
Q2 2024 | 2.5% | 3.9% | -144 bps | Miss |
Q3 2024 | 5.4% | 4.8% | +56 bps | Beat |
Q4 2024 | 5.2% | 5.8% | -64 bps | Miss |
Q1 2025 | 3.1% | 3.5% | -42 bps | Miss |
Q2 2025 | 5.6% | 5.6% | 0 bps | In Line |
Q3 2025 | 3.4% | 3.7% | -29 bps | Miss |
Q4 2025 | 5.1% | 4.2% | +93 bps | Beat |
Q1 2026 | 3.0% | 0.6% | +248 bps | Large Beat |
Quarter | Reported | Consensus | Surprise (%) | Result |
Q2 2024 | $0.83 | $0.79 | +5.1% | Beat |
Q3 2024 | $0.95 | $0.85 | +11.6% | Beat |
Q4 2024 | $0.65 | $0.66 | -1.5% | Miss |
Q1 2025 | $0.74 | $0.66 | +11.8% | Beat |
Q2 2025 | $0.73 | $0.69 | +6.6% | Beat |
Q3 2025 | $0.73 | $0.71 | +2.8% | Beat |
Q4 2025 | $0.72 | $0.69 | +4.0% | Beat |
Q1 2026 | $0.67 | $0.61 | +9.7% | Beat |
Pattern: MDLZ has beaten adj. EPS consensus in 7 of the last 8 quarters, with an average beat of ~6%. On organic revenue growth, the record is more mixed (4 misses, 3 beats, 1 in-line over 8 quarters), but the Q1 2026 beat of +248 bps was the largest in the series — driven by a very low bar set by the Street. With Q2 consensus at just 0.75%, the bar is again low, but the comp from Q2 2025 (5.6%) is the toughest in the year.
Source: Visible Alpha Consensus and Actuals Data
Key Takeaway: Management reaffirmed full-year 2026 guidance on the Q1 call rather than raising it, explicitly absorbing Middle East conflict headwinds and signaling a preference to reinvest any EPS upside back into the business. Tone has shifted from cautiously optimistic to strategically patient — confident in the 2027 recovery thesis but unwilling to guide above the current range until H2 visibility improves.
Metric | Initial Guidance (Q1 2026 Earnings Call, Apr 28) | Revised Guidance | Current Consensus | Note |
FY 2026 Organic Revenue Growth | Low single-digit (reaffirmed) | — | ~1.7% | Unchanged; consensus sits at low end of guidance range, reflecting North America uncertainty |
FY 2026 Adj. EPS (Diluted-Operating) | ~$3.04–$3.05 (reaffirmed; flat to modest growth on CC) | — | $3.05 | Unchanged; management explicitly stated EPS upside would be reinvested, not flowed through |
FY 2026 Free Cash Flow | ~$3.2B (reaffirmed) | — | $3.24B | Unchanged; consensus in line with guidance |
Volume/Mix Trajectory | Sequential improvement through 2026; NA volume/revenue inflection in H2 | — | FY vol/mix ~0.05% | Management guided for positive inflection in NA in H2; consensus reflects cautious recovery |
Gross Margin | Headwind in H1 (cocoa inventory phasing); recovery in H2 as costs normalize | — | Q2 gross profit ~$3.02B | Middle East conflict adds incremental cost headwind in unhedged markets in H2 |
Emerging Markets Organic Growth | Mid-to-high single digit; volume-led growth engine | — | Implied ~5–6% for FY | Q1 EM grew 6.3%; management remains very confident in EM as sustainable growth engine |
FY 2027 EPS Growth | Strong growth; cocoa deflationary; margin expansion | — | N/A (FY27 not in scope) | Management's primary forward signal; any 2026 upside reinvested to build 2027 momentum |
Key Takeaway: Estimates for Q2 2026 have been essentially flat since the Q1 print — organic growth consensus moved only marginally from ~0.96% to ~0.75%, and adj. EPS barely budged ($0.678 to $0.679). The lack of downward revision despite Middle East headwinds is mildly encouraging, suggesting the Street has already baked in a soft quarter and is not positioned for further cuts.
KPI (Period) | Estimate ~5 Days Post Q1 Earnings (May 5, 2026) | Current Consensus | Estimate Δ (%) | Initial Guidance (Q1 Call) | Current Guidance | Guidance Δ | Consensus vs. Guidance (%) |
Organic Growth % (Q2 2026) | 0.96% | 0.75% | -22 bps | Low single-digit | Unchanged | — | Below midpoint |
Organic Growth % (FY 2026) | 1.84% | 1.74% | -10 bps | Low single-digit | Unchanged | — | At low end of range |
Adj. EPS (Q2 2026) | $0.678 | $0.679 | +0.1% | Flat to modest growth (CC) | Unchanged | — | In line |
Adj. EPS (FY 2026) | $3.054 | $3.045 | -0.3% | ~$3.04–$3.05 | Unchanged | — | At midpoint |
Net Revenue (Q2 2026) | $9.25B | $9.23B | -0.2% | ~$39.9–40.1B FY | Unchanged | — | In line |
Net Revenue (FY 2026) | $40.07B | $39.99B | -0.2% | ~$39.9–40.1B FY | Unchanged | — | At midpoint |
Estimates have been remarkably stable since the Q1 print, with organic growth and EPS revisions essentially flat. This stability is notable given the Middle East conflict headwinds flagged on the Q1 call — it suggests the Street has already priced in a soft Q2 and is not expecting further guidance cuts. The gap between consensus organic growth (~0.75% for Q2, ~1.74% for FY) and management's "low single-digit" guidance range implies the Street is positioned at the low end, creating asymmetric upside if emerging markets sustain Q1 momentum.
Source: Visible Alpha Consensus and Actuals Data
Key Takeaway: MDLZ has modestly outperformed XLP (+3.6% vs. +2.7%) since the Q1 earnings date, but the move has been driven by multiple stabilization rather than estimate revisions — with EPS consensus barely moving, the stock's recovery from the post-earnings dip reflects sentiment improvement and sector rotation into defensive names, not a fundamental re-rating.
MDLZ vs. XLP (Consumer Staples ETF) — Indexed to 100 at Q1 2026 Earnings Date (April 28, 2026). Source: Stock Price Data.
Performance Summary (Apr 28 – Jul 24, 2026):
Key Observations: The stock's inability to hold the June 10 peak (~$64) despite no negative news suggests the market is waiting for Q2 confirmation before re-rating. The June 30 selloff (to $57.84) appears technical/rebalancing-driven rather than fundamental. Analyst consensus remains "Moderate Buy" with an average price target of ~$67–$68, implying ~11–12% upside from current levels. The stock trades at a discount to historical averages, with the market focused on 2026 execution rather than the 2027 recovery thesis.
Source: Stock Price Data (Yahoo Finance)
Key Takeaway: Peer commentary from Q2 2026 reporting season is broadly constructive for MDLZ — Nestlé's H1 2026 results confirm that snacking categories are holding up in emerging markets and that cocoa/coffee cost tailwinds are building for H2, while General Mills and Campbell's flag a still-stressed North American consumer that validates MDLZ's cautious NA tone. The most important read-through is Nestlé's confirmation that lower cocoa costs are flowing through the P&L in H2 2026, which is a direct positive signal for MDLZ's gross margin trajectory.
Note: Only forward-looking commentary and commentary about the current reporting period (Q2 2026 / H1 2026 / FY2027 outlook) is included below. Backward-looking Q1 results commentary from peers has been excluded.
Most Relevant Peer: Nestlé is the closest global snacking/confectionery peer to MDLZ, with overlapping categories (chocolate, biscuits, snacks) and similar geographic exposure (Europe, emerging markets, North America).
MDLZ Read-Through Summary: Nestlé's H1 2026 results are the most important peer read-through for MDLZ. The confirmation of lower cocoa/coffee costs flowing through the P&L in H2, sustained EM momentum (especially India), and manageable Middle East headwinds all support MDLZ's Q2 2026 setup. The European confectionery delistings are a mild watch item but appear company-specific to Nestlé.
Relevance: GIS is a key North American packaged food peer with significant biscuit/snack exposure (Goldfish, Totino's, Chex Mix). Its commentary on the NA consumer and category health is directly relevant to MDLZ's North America biscuit business.
MDLZ Read-Through Summary: GIS confirms the NA consumer remains stressed and category growth is soft, validating MDLZ's cautious NA guidance. The channel bifurcation (value + premium outperforming mainstream) is consistent with MDLZ's strategy. No major surprises — the read-through is broadly neutral to slightly negative for MDLZ's NA biscuit volumes in Q2.
Relevance: CPB's Snacks division (Goldfish, Pepperidge Farm, salty snacks) competes directly with MDLZ in the NA biscuit/cracker aisle. Its commentary on snacking demand and the NA consumer is a direct read-through.
MDLZ Read-Through Summary: CPB's commentary is a mild negative read-through for MDLZ's NA biscuit volumes (category pressure persists) but confirms the Middle East inflation headwind is industry-wide and manageable. The value/club channel strength is a positive read-through for MDLZ's channel strategy.
Relevance: KHC is a major NA packaged food peer. Its Q2 2026 and H2 2026 forward guidance is directly relevant to MDLZ's NA consumer outlook.
MDLZ Read-Through Summary: KHC's Q2 guidance is more negative than what MDLZ is likely to report (KHC has more SNAP/staples exposure), but the broader signals — NA consumer stress, rational pricing, EM improvement — are consistent with MDLZ's own commentary. The SNAP headwind is less relevant for MDLZ's snacking portfolio.
Relevance: CAG's permissible snacking portfolio (meat snacks, popcorn, seeds) competes at the margin with MDLZ's better-for-you snacking brands. Its FY2027 outlook is relevant for the NA snacking category.
MDLZ Read-Through Summary: CAG's commentary confirms the NA consumer is value-conscious and category volumes are under pressure, but the permissible snacking outperformance validates MDLZ's better-for-you innovation strategy. The cost inflation signals are consistent with MDLZ's own guidance.
Peer | Report Date | Key Theme | MDLZ Read-Through | Signal |
Nestlé (NESN) | Jul 23, 2026 | Cocoa/coffee cost tailwind in H2; EM strength; ME conflict headwind manageable | Gross margin recovery on track; EM momentum confirmed | Positive |
General Mills (GIS) | Jul 1, 2026 | NA consumer stressed; category soft; value/premium bifurcation | Validates cautious NA tone; channel strategy confirmed | Neutral |
Conagra (CAG) | Jul 15, 2026 | Consumer value-conscious; permissible snacking outperforming; inflation 5–6% | Better-for-you innovation validated; cost pressure manageable for MDLZ (cocoa deflationary) | Neutral |
Campbell's (CPB) | Jun 8, 2026 | NA snacking under pressure; value/club channels strong; ME inflation confirmed | NA biscuit category soft; club channel strategy validated | Mild Negative |
Kraft Heinz (KHC) | May 6, 2026 | Q2 top line -3% to -5%; SNAP headwind; rational pricing; EM improving | Company-specific issues; SNAP less relevant for MDLZ; pricing rational | Neutral (MDLZ less exposed) |
Key Takeaway: The most important development since Q1 earnings is Nestlé's July 23 confirmation that lower cocoa costs are flowing through the P&L in H2 2026 — a direct positive signal for MDLZ's gross margin recovery thesis. No company-specific negative catalysts have emerged since the Q1 print.
Key Takeaway: No open-market buys or discretionary sells since the Q1 earnings date. All transactions are routine compensation-related grants (code A = award) or minor trust transfers. The absence of any open-market selling by executives is mildly constructive — insiders are not using the post-earnings stock strength to reduce exposure.
Name | Title | Transaction Type | Shares | Date | Note |
Amit Banati | EVP and CFO | Award (Stock Options) | 122,210 options | Jul 1, 2026 | Routine compensation award; not an open-market purchase |
Amit Banati | EVP and CFO | Award (Common Stock) | 20,370 shares | Jul 1, 2026 | Routine compensation award; not an open-market purchase |
Ertharin Cousin | Director | Award (Common Stock) | 3,525 shares | May 20, 2026 | Annual director compensation grant |
Nancy McKinstry | Director | Award (Common Stock) | 3,525 shares | May 20, 2026 | Annual director compensation grant |
Brian James McNamara | Director | Award (Common Stock) | 3,525 shares | May 20, 2026 | Annual director compensation grant |
Jorge S. Mesquita | Director | Award (Common Stock) | 3,525 shares | May 20, 2026 | Annual director compensation grant |
Jane Nielsen | Director | Award (Common Stock) | 3,525 shares | May 20, 2026 | Annual director compensation grant |
Paula A. Price | Director | Award (Common Stock) | 3,525 shares | May 20, 2026 | Annual director compensation grant |
Patrick Siewert | Director | Award (Common Stock) | 3,525 shares | May 20, 2026 | Annual director compensation grant |
Cees 't Hart | Director | Award (Common Stock) | 3,525 shares | May 20, 2026 | Annual director compensation grant |
Michael Todman | Director | Award (Common Stock) | 3,525 shares | May 20, 2026 | Annual director compensation grant |
Brian Stevens | SVP, CTR & Chief Accounting Officer | Open Market Sale (Trust) | 63 shares (trust) + 1 share (trust) | Apr 30 – May 1, 2026 | Small trust-level sales; de minimis in size; not a discretionary insider sell signal |
All transactions since the Q1 2026 earnings date (April 28, 2026) are compensation-related awards (code A) or de minimis trust-level sales. There are no open-market purchases (code P) or discretionary open-market sales (code S) by executives. The nine director grants on May 20 are routine annual compensation. The CFO's July 1 award (122,210 options + 20,370 shares) is a standard long-term incentive grant. The absence of any discretionary selling by management or directors heading into Q2 earnings is a mild positive signal — insiders are not reducing exposure despite the stock trading near the top of its recent range.
Source: Insider Transaction Data (SEC Form 4)